Project Updates

Location: Oceanside, California

Project type: Commercial biologics manufacturing facility

Expected Start of Operations: Early 2025

Owner: Genentech

Genentech, a member of Roche Group, will build a next-generation biologics manufacturing facility at its existing campus in Oceanside, California, for sustainable production of small-batch commercial biologics. A ground-breaking ceremony for the new manufacturing facility took place in February 2023.

Location: Kigali, Rwanda 

Project type: Vaccine manufacturing facility 
Start of Construction: June 2022 

Owner: BioNTech

BioNTech is building its first modular mRNA vaccine manufacturing facility in Kigali, Rwanda, to promote sustainable vaccine production and end-to-end vaccine supply in African Union member states. The project is expected to create around 100 jobs by 2024.

Location: Sanford, North Carolina 

Project type: Biologics manufacturing site 

Estimated Investment: $213m 

Area: 120,000²

Abzena is building a current good manufacturing practice (cGMP) manufacturing facility for mammalian biologics in Sanford, North Carolina. The facility will expand the company’s manufacturing capacity to meet customer demand. Abzena’s new manufacturing site is expected to create 325 local jobs.